 | • レポートコード：MRC2303B044 • 出版社/出版日：Mordor Intelligence / 2023年3月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書では、世界の緑膿菌感染治療市場規模が予測期間中に年平均4.7％上昇すると推測されています。本調査書では、緑膿菌感染治療の世界市場を広く調査・分析をし、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（単剤療法、併用療法）分析、投与経路別（経鼻、経口、静脈注射）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などを整理しています。また、本書には、AbbVie Inc. (Allergan PLC)、Teva Pharmaceutical Industries Ltd、Pfizer Inc.、Lupin Pharmaceuticals Inc.、AstraZeneca PLC、Merck & Co. Inc.、Bristol Myers Squibb Company、Johnson & Johnsonなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の緑膿菌感染治療市場規模：治療別 - 単剤療法における市場規模 - 併用療法における市場規模 ・世界の緑膿菌感染治療市場規模：投与経路別 - 経鼻型緑膿菌感染治療の市場規模 - 経口型緑膿菌感染治療の市場規模 - 静脈注射型緑膿菌感染治療の市場規模 ・世界の緑膿菌感染治療市場規模：地域別 - 北米の緑膿菌感染治療市場規模 アメリカの緑膿菌感染治療市場規模 カナダの緑膿菌感染治療市場規模 メキシコの緑膿菌感染治療市場規模 … - ヨーロッパの緑膿菌感染治療市場規模 ドイツの緑膿菌感染治療市場規模 イギリスの緑膿菌感染治療市場規模 フランスの緑膿菌感染治療市場規模 … - アジア太平洋の緑膿菌感染治療市場規模 中国の緑膿菌感染治療市場規模 日本の緑膿菌感染治療市場規模 インドの緑膿菌感染治療市場規模 … - 南米/中東の緑膿菌感染治療市場規模 南アフリカの緑膿菌感染治療市場規模 ブラジルの緑膿菌感染治療市場規模 アルゼンチンの緑膿菌感染治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The Pseudomonas aeruginosa infection treatment market is expected to register a CAGR of nearly 4.7% during the forecast period.
Pseudomonas aeruginosa is a common encapsulated, Gram-negative, rod-shaped bacterium that can cause disease in humans. P. aeruginosa is a multidrug-resistant pathogen recognized for its ubiquity, intrinsically advanced antibiotic resistance mechanisms, and association with serious illnesses, including hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes.
The ongoing outbreak of the COVID-19 pandemic impacted the pharmaceutical industry positively. It also affected the Pseudomonas aeruginosa infection treatment market. Recently, “oral ciprofloxacin” drug products have been used to treat P. auregenosa infected patients with COVID-19 pneumonia. The expanded therapy for P. aeruginosa and methicillin-resistant S aureus reduces antibiotic use in patients. The American Thoracic Society and Infection Diseases Society of America provide a guideline for the treatment of adults with community-acquired pneumonia and COVID-19. These factors propel the growth of the market.
The major factors such as the growing patient population infected with Pseudomonas aeruginosa infection, increasing incidence of infections associated with it such as pneumonia, cystic fibrosis, and urinary tract infections, increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of the Pseudomonas aeruginosa infection market.
The prevalence of hospital-acquired infections has increased in recent years. According to an article titled ‘Community-Acquired Pneumonia’ published in August 2021, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. This has led to an increase in research and development in understanding P. aeruginosa. As a result, many drugs are in the pipeline for the treatment of this infection. These factors have helped the growth of the market, and they are expected to help in the future as well.
However, as stated earlier, P. aeruginosa shows the ability of drug resistance. As a result, many drug developers with limited funds are dissuaded from the market. This factor has been hindering the market growth.
Pseudomonas Aeruginosa Infection Treatment Market Trends
Combination Therapy is Expected to Dominate the Market
Combination therapy for the treatment of P. aeruginosa is administered due to different considerations – first, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending; second, to avoid the emergence of resistance during treatment; and third, due to possible synergistic activity resulting in better clinical outcome.
According to an article titled ‘Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa’ published in November 2021, antimicrobial susceptibility testing showed that P. aeruginosa strains were highly resistant to ceftazidime (88.9%) and cefepime (82.2%), which were the most prevalent among wound infections. Imipenem and amikacin were the most effective drugs with the least resistance percentage (28.9%). The research concluded that the drug combination viewed a statistically significant reduction in bacterial counts when receiving definite combination therapy, compared to monotherapy, and combination therapy showed good results.
Due to the benefits of combination therapy over monotherapy, this segment is expected to grow during the forecast period.
North America is Expected to Dominate the Market
As per a report by the Agency for Healthcare Research and Quality, 2019, approximately 1 of every 25 hospitalized patients in the United States has a hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contracting one of these infections annually. According to the American Association for the Advancement of Science, the proportion of patients with a hospital-acquired infection was 7.9% in 2017 in Canadian hospitals. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.
According to an article titled ‘Community-Acquired Pneumonia’ published in August 2021, The annual incidence in the United States is 24.8 cases per 10,000 adults, with higher rates as people get older. Pneumonia is the eighth most common cause of mortality and the top among infectious diseases. Patients hospitalized in the intensive care unit have a death rate of up to 23%. Additionally, as per the publication in Biomedical and Pharmacology Journal 2021, women under 19 years affected with COVID-19 also developed pneumonia. The nationwide prevalence of pneumonia was 2.81%, with the highest prevalence of 13.77% in Veracruz, followed by 12.66% in Nayarit, 12.08% in Quintana Roo, and 0.71% in Durango. The attributable fractions and odds ratios were estimated using Durango as the baseline group. The increasing prevalence of infections related to the respiratory tract is expected to create more demand in the Pseudomonas aeruginosa infection treatment market in the North American region.
However, the United States and Canada have a developed and well-structured healthcare system. These systems also encourage research and development. These policies encourage global players to enter the United States and Canada. As a result, these countries enjoy the presence of many global market players. As the increasing demand is met by the presence of global players in the region, the market is further expected to grow.
Pseudomonas Aeruginosa Infection Treatment Market Competitor Analysis
The majority of the Pseudomonas aeruginosa infection treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their positions in the market. Moreover, Asia-Pacific is witnessing an emergence of some small players due to the rise in awareness. This has also helped the market grow.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hospital-acquired Infections
4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
4.3 Market Restraints
4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 Treatment
5.1.1 Monotherapy
5.1.2 Combination Therapy
5.2 Route of Administration
5.2.1 Nasal
5.2.2 Oral
5.2.3 Intravenous
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan PLC)
6.1.2 Teva Pharmaceutical Industries Ltd
6.1.3 Pfizer Inc.
6.1.4 Lupin Pharmaceuticals Inc.
6.1.5 AstraZeneca PLC
6.1.6 Merck & Co. Inc.
6.1.7 Bristol Myers Squibb Company
6.1.8 Johnson & Johnson
7 MARKET OPPORTUNITIES AND FUTURE TRENDS